AbbVie Inc. (BCBA:ABBV)

Market Cap	428.74T
Revenue (ttm)	61.56T
Net Income (ttm)	4.46T
Shares Out	n/a
EPS (ttm)	2,510.97
PE Ratio	96.16
Forward PE	15.35
Dividend	417.13 (1.70%)
Ex-Dividend Date	Apr 15, 2025

Volume	1,398
Average Volume	2,943
Open	24,600
Previous Close	24,700
Day's Range	24,325 - 24,650
52-Week Range	18,325 - 27,925
Beta	n/a
RSI	66.52
Earnings Date	Jul 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD